MediciNova Receives Notice of Allowance for New Patent

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
20
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Japan

LA JOLLA, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV ) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001)  for the treatment of “fibrosis” which includes a broad range of fibrosis / fibrotic disease in different organs due to different causes.

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than June 2035. The allowed claims cover a composition for inhibiting or treating fibrosis using MN-001 or MN-002. The allowed claims cover oral administration including liquid and solid dosage forms.

Yuichi Iwaki, MD, PhD, President and CEO of MediciNova, Inc. commented, "We are very pleased to receive notice that this new patent will be granted as the claims are broad enough to cover MN-001 for the treatment of many forms of fibrosis and fibrotic disease. A similar patent that extensively covers the treatment of various forms of fibrosis / fibrotic disease has already been approved by the U.S. Patent Office in 2016. We believe this patent could substantially increase the potential value of MN-001 as MN-001’s broad anti-fibrotic activity enables us to pursue clinical development in various types of fibrosis.”

About MN-001

MN-001 (tipelukast) is a novel, orally bioavailable small molecule compound thought to exert its effects through several mechanisms to produce its anti-inflammatory and anti-fibrotic activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). The 5-LO/LT pathway has been postulated as a pathogenic factor in fibrosis development, and MN-001's inhibitory effect on 5-LO and the 5-LO/LT pathway is considered to be a novel approach to treat fibrosis. MN-001 has been shown to down-regulate expression of genes that promote fibrosis including LOXL2, Collagen Type 1 and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation including CCR2 and MCP-1. In addition, histopathological data shows that MN-001 reduces fibrosis in multiple animal models.  

About MediciNova

MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S. market. MediciNova's current strategy is to focus on MN-166 (ibudilast) for neurological disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), substance dependence (e.g., alcohol use disorder, methamphetamine dependence, opioid dependence) and glioblastoma (GBM), and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). MediciNova’s pipeline also includes MN-221 (bedoradrine) and MN-029 (denibulin). For more information on MediciNova, Inc., please visit www.medicinova.com .

Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166, MN-221, MN-001, and MN-029. These forward-looking statements may be preceded by, followed by or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166, MN-221, MN-001, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2017 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

INVESTOR CONTACT: Geoff O'Brien Vice President MediciNova, Inc. info@medicinova.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Chemours Legal Succession Gets a Long Transition Runway

Updated Category News Views 201

A corporate-law handoff rarely sets pulses racing, but this one deserves a proper look. Chemours is replacing its long-serving general counsel while keeping the departing executive in the building for four additional months. That is not flashy, and thank goodness for that. In a global chemicals company, legal leadership touches regulation, compliance, governance,...

Continue Reading
Nvidia Faces SEC Probe Report and New Lawsuit Stakes

Updated Category News Views 40

Silicon Valley's favorite growth machine has stumbled into the sort of fog investors hate most: regulatory questions, leadership upheaval, and a stock-price reaction with no clean answer attached. Reports cited in the lawsuit update say the Securities and Exchange Commission has opened a civil probe into NVIDIA's investor disclosures following former CEO Jensen Huang's...

Continue Reading
PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 131

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
AbbaDox Finds Follow-Up Scans Lost in the Shuffle

Updated Category News Views 22

A six-month recommendation has a nasty habit of disappearing beneath today’s emergencies. That is the unglamorous, important problem AbbaDox is trying to solve in outpatient radiology: not reading the scan, but making sure a future scan recommendation actually gets reviewed, ordered, and scheduled. For investors watching healthcare operations software, this is the sort...

Continue Reading
Teciem’s New CFO Puts Financial Discipline Behind Growth

Updated Category News Views 43

A finance chief moving continents is not decorative corporate wallpaper. Teciem’s decision to appoint Jesús Rueda Molins as chief financial officer says the company wants its next growth chapter run with more than product ambition and executive slogans. It wants somebody holding the purse strings who already knows the machinery, the customers and the people making the...

Continue Reading
Radiology Staffing Gap Deepens as Imaging Demand Rises

Updated Category News Views 112

An imaging order does not mean much if nobody is available to read it, and that plain operational fact sits at the center of Medicus Healthcare Solutions' 2026 report on the radiologist shortage. The report's projected gap of 2,450 full-time-equivalent radiologists in 2027 is troubling enough. Its estimate of a 4,130 FTE shortfall by 2032 is the part that should make...

Continue Reading
SK hynix Faces Fresh DRAM Collusion Risk for Investors

Updated Category News Views 102

A Memory Market Win Can Turn Sour Fast Nothing rattles a chip story quite like the word collusion showing up beside a judge’s ruling. SK hynix had been riding a powerful memory-market narrative, but investors got a blunt reminder on November 15, 2026: a proposed U.S. class action accusing SK hynix, Samsung Electronics, and Micron of restricting DRAM supply to raise...

Continue Reading
Vail’s Board Fight Puts Strategy Under a Sharp Lens

Updated Category News Views 105

Fresh snow does not make a boardroom dispute disappear. Vail Resorts has put out an investor presentation ahead of its December 14, 2026 annual meeting, asking shareholders to support all nine of management’s director nominees on its white proxy card. That is the formal message. The real message is plainer: NYSE:MTN knows this election has become a test of whether...

Continue Reading
Candel’s BLA Delay Puts Disclosure Timing Under Fire

Updated Category News Views 0

A December filing turned into a mid-2027 wait, and Candel shareholders absorbed the damage in one ugly trading session. On November 13, shares of Candel Therapeutics fell 26% after the company disclosed that its biologics license application, or BLA, for aglatimagene in prostate cancer was no longer expected in December 2026. The revised plan is to submit in the middle of...

Continue Reading
The Hanover Survey Puts Small-Business Trust on Trial

Updated Category News Views 275

A dark storefront can apparently erase goodwill faster than plenty of owners want to admit. The Hanover Insurance Group's 2026 Small Business Pulse Report found that 60% of surveyed consumers would temporarily buy from a competitor if their preferred small business shut unexpectedly. More than half would start looking elsewhere within a week. That is not a cute...

Continue Reading

Top 5 Most Recently Viewed Articles

TCL's Innovative Initiatives: Sustainability and Creativity Unite

Updated Category News Views 304

TCL's Commitment to Innovation and Sustainability At IFA 2024, TCL, a prominent global technology brand, showcased its unwavering dedication to innovation and sustainability. This year marks TCL's 14th consecutive appearance at the event, where the company highlighted two key initiatives: TCLGreen and TCLArt. These initiatives have attracted considerable attention as they...

Continue Reading
Western Metallica Closes Private Placement to Boost Copper Projects

Updated Category News Views 209

Western Metallica's Successful Private Placement Financing Western Metallica Resources Corp. (TSXV: WMS) has successfully completed its non-brokered private placement financing. This strategic decision allowed the company to issue a significant number of units at an appealing price point. By offering 10,833,345 units at $0.03 each, Western Metallica raised gross proceeds...

Continue Reading
Astrion's New Leadership Team Set to Drive Future Innovations

Updated Category News Views 250

Astrion Unveils Dynamic Executive Leadership Team Astrion, a leader in providing advanced engineering services and mission support to government sectors, has recently announced an exciting new executive leadership team. This strategic move aligns with their ongoing mission to deliver innovative solutions following the acquisition of Axient. With industry veteran Dave...

Continue Reading
Keyera Corp. Schedules Conference Call for Q3 2024 Results

Updated Category News Views 119

Keyera Corp. Schedules 2024 Q3 Results Conference Call Keyera Corp. has announced its timeline for the release of third-quarter results. Investors and interested parties are encouraged to take note of the important dates surrounding this announcement. When to Expect the Financial Results The financial results are set to be released before the market opens on November 14,...

Continue Reading
Netflix Partners with WWE to Revitalize Global Wrestling Fanbase

Updated Category News Views 411

Netflix and WWE Join Forces for a Live Streaming Revolution In an exciting new venture, Netflix has entered the world of live programming by teaming up with World Wrestling Entertainment (WWE) to stream its flagship show, "Raw." This collaboration marks a significant shift in how wrestling fans will experience their favorite matches, bringing the thrill of live...

Continue Reading